



Preliminary 2005 Multiple Myeloma Guidelines

(Consider Clinical Trial in all Settings)

Initial Therapy

Pre- high-dose chemo with ASCR:

- ♦ Thalidomide (100-200mg qd) + Dexamethasone (40mg qd on d1-4, 9-12, 17-20 Q28days)
- ♦ Dexamethasone (40mg qd on d1-4, 9-12, 17-20 Q28days)
- ♦ VAD (vincristine 0.4mg/d as CIV x 96hrs, adriamycin 9mg/m²/d as CIV x 96hrs, dexamethasone)
- ♦ DVD (Doxil 40mg/m² d1, vincristine 1.4mg/m² [max 2mg] d1, dexamethasone 40mg qd d1-4) (*Cat 2B*)

No high-dose chemotherapy (no ASCR):

- ♦ Melphalan (6mg/m² qd d1-7) / Prednisone (60mg qd d1-7)
- ♦ Dexamethasone (pulse)
- ♦ Thalidomide +/- Dexamethasone (pulse)

Maintenance Therapy

Post-high-dose chemo with ASCR:

- ♦ Thalidomide 50mg QOD
- ♦ Prednisone 50mg QOD (*Cat 1*)

Second/Third Line (refractory or relapsed):

- ♦ Thalidomide +/- Dexamethasone (pulse)
- ♦ Dexamethasone (pulse)
- ♦ Prednisone (continuous daily 5-10mg)
- ♦ Bortezomib (1.0-1.3mg/m² on days 1, 4, 8 & 11 Q21 days) +/- Dexamethasone (pulse)
- ♦ Melphalan +/- Prednisone (doses as above)
- ♦ MAC (Melphalan, Arsenic, Ascorbic acid)
- ♦ Cytoxan (1200mg/m² Q21)
- ♦ Lenalidomide (pending)

All recommendations are category **2A**, unless otherwise specified